Table 2.

Effect of peptides on neutralization of anti—Factor Xa activity of UFH in patient plasma


Patient number  

1-H  

2-H  

3-H  
Anti—Factor Xa activity at collection, U/mL   0.36   0.49   0.27  
U/mL anti-FXa activity neutralized in the presence of 6 mg/mL peptide     
Peptide    
    Protamine   0.357 ± 0.030   0.408 ± 0.011   0.274 ± 0.010  
    (ARKKAAKA)4  0.282 ± 0.196   0.254 ± 0.053   0.299 ± 0.050  
    C(ARKKAAKA)4C   0.099 ± 0.064   0.248 ± 0.011   0.172 ± 0.005  
    (ARKKAAKA)3ARKKCAKA   0.368 ± 0.022   0.324 ± 0.015   0.187 ± 0.020  
    ARKKAAKA(A16)ARKKAAKA   0.020 ± 0.016   0.017 ± 0.018   0  
    (ARKKAAKA)3VLVLVLVL*  0.242 ± 0.006   0.421 ± 0.040   0.285 ± 0.166  
    (ARKKARA)6  0.228 ± 0.033   0.317 ± 0.082   0.176 ± 0.003  
    (ARKKAAKA)3(VL)3  0.203 ± 0.013   0.368 ± 0.033   0.195 ± 0.005  
    (VL)2(ARKKAAKA)3ARKKCAKA
 
0.228 ± 0.019
 
0.324 ± 0.025
 
0.207 ± 0.016
 

Patient number  

1-H  

2-H  

3-H  
Anti—Factor Xa activity at collection, U/mL   0.36   0.49   0.27  
U/mL anti-FXa activity neutralized in the presence of 6 mg/mL peptide     
Peptide    
    Protamine   0.357 ± 0.030   0.408 ± 0.011   0.274 ± 0.010  
    (ARKKAAKA)4  0.282 ± 0.196   0.254 ± 0.053   0.299 ± 0.050  
    C(ARKKAAKA)4C   0.099 ± 0.064   0.248 ± 0.011   0.172 ± 0.005  
    (ARKKAAKA)3ARKKCAKA   0.368 ± 0.022   0.324 ± 0.015   0.187 ± 0.020  
    ARKKAAKA(A16)ARKKAAKA   0.020 ± 0.016   0.017 ± 0.018   0  
    (ARKKAAKA)3VLVLVLVL*  0.242 ± 0.006   0.421 ± 0.040   0.285 ± 0.166  
    (ARKKARA)6  0.228 ± 0.033   0.317 ± 0.082   0.176 ± 0.003  
    (ARKKAAKA)3(VL)3  0.203 ± 0.013   0.368 ± 0.033   0.195 ± 0.005  
    (VL)2(ARKKAAKA)3ARKKCAKA
 
0.228 ± 0.019
 
0.324 ± 0.025
 
0.207 ± 0.016
 

Blood was collected from patients treated with continuous infusion of UFH and the anti—Factor Xa activity was monitored as described in the text. All data are for assays with 6 μg/mL peptide.

*

The data for the most effective peptide, (ARKKAAKA)3VLVLVLVL.

or Create an Account

Close Modal
Close Modal